Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer

• Published in: European journal of nuclear medicine and molecular imaging 2005-11, Vol.32 (11), p.1253-1258
• Main Authors: Nakai, Takako, Okuyama, Chio, Kubota, Takao, Yamada, Kei, Ushijima, Yo, Taniike, Keiko, Suzuki, Takako, Nishimura, Tsunehiko
• Format: Article
• Language: English
• Subjects: Bone Neoplasms - diagnostic imaging; Bone Neoplasms - pathology; Bone Neoplasms - secondary; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - pathology; Female; Fluorodeoxyglucose F18; Humans; Osteoblasts - diagnostic imaging; Positron-Emission Tomography - methods; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Technetium Tc 99m Medronate - analogs & derivatives
• ISSN: 1619-7070; 1619-7089
• DOI: 10.1007/s00259-005-1842-8

The purpose of this study was to investigate the pitfalls of using 2-[18F]-fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) for the evaluation of osteoblastic bone metastases in patients with breast cancer by comparing it with (99m)Tc-hydroxymethylene diphosphonate bone scintigraphy. Among the 89 breast cancer patients (mean age 59+/-15 years) who had undergone both FDG-PET and bone scintigraphy within 1 month between September 2003 and December 2004, 55 with bone metastases were studied. The bone metastases were visually classified by multi-slice CT into four types according to their degree of osteosclerosis and osteolysis-osteoblastic, osteolytic, mixed and invisible-and compared in terms of tracer uptake on FDG-PET or bone scintigraphy and SUV(mean) on FDG-PET. Differences in the rate of detection on bone scintigraphy and FDG-PET were analysed for significance by the McNemar test. The sensitivity, specificity and accuracy of bone scintigraphy were 78.2%, 82.4% and 79.8% respectively, and those of FDG-PET were 80.0%, 88.2% and 83.1%, respectively, revealing no significant differences. According to the CT image type, the visualisation rate of bone scintigraphy/FDG-PET was 100%/55.6% for the blastic type, 70.0%/100.0% for the lytic type, 84.2%/94.7% for the mixed type and 25.0%/87.5% for the invisible type. The visualisation rates of bone scintigraphy for the blastic type and FDG-PET for the invisible type were significantly higher. The SUV(mean) of the blastic, lytic, mixed and invisible types were 1.72+/-0.28, 4.14+/-2.20, 2.97+/-1.98 and 2.25+/-0.80, respectively, showing that the SUV(mean) tended to be higher for the lytic type than for the blastic type. FDG-PET showed a low visualisation rate in respect of osteoblastic bone metastases. Although FDG-PET is useful for detection of bone metastases from breast cancer, it is apparent that it suffers from some limitations in depicting metastases of the osteoblastic type.